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Abstract 
Purpose: To investigate the inhibitory effect of wortmannin on inhibition of BT-20 and BT-474 breast 
cancer cells in Athymic nu/nu mice model.  
Methods: Forty Athymic nu/nu mice were randomly assigned to 4 groups of 10 each, namely, BT-20 
control, BT-20 treatment, BT-474 control and BT-474 treatment groups. The mice were injected with 2.5 
x 105 BT-20 and BT-474 cells under anesthesia. Those in the treatment groups were given wortmannin 
(7 mg/kg) in DMSO daily intraperitoneally whereas the animals in control groups received an equal 
volume of DMSO for 21 days after the cancer attained palpable stage. Western blot analysis was 
carried out using enhanced chemiluminescence reagent while Protean IEF cell unit was used for 1-D 
electrophoresis. 
Results: The results showed a significant decrease in the growth of the tested cancer cell lines on 
treatment with wortmannin at 7 mg/kg daily for 21 days. The volume of tumor in the treatment group 
was reduced to 42.72 ± 9.45 compared to 79.43 ± 17.11 mm3 in the control group after 21 days 
treatment (p < 0.005). It also changed the expression of microRNA in BT-20 cells. Exposure of BT-20 
cells to wortmannin for 24 h resulted in the altered expression of proteomes. Wortmannin treatment 
increased the expression of miRs including miR 19a/b, 22, 29b/c, 181c/d, 195 and 663. Western blot 
data showed increase in the expression of NME1 (NM23 H1) and reduction in the expression of 
vimentin after treatment with wortmannin.  
Conclusion: Wortmannin can be of benefit in the treatment of human breast cancer. 
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Breast carcinoma is a challenging health issue at 
present affecting one out of every eight women, 
especially in US [1]. It is estimated that about 20 
% of the patients with primary breast cancer 
rapidly develop distant metastases leading to 
higher mortality rates [2]. The median survival 
period for breast cancer patients is around three 
years [2]. Breast cancer has been found 
commonly in women and its proportion in men is 
very low [3]. Triple negative breast cancer 
(TNBC) comprises a group of heterogeneous 
diseases which are prevalent among African and 
American women and is more aggressive 
compared to other cancers [4-6]. It has been 
reported that TNBC spreads rapidly to distant 
tissues and leads to mortality within very short 
time span of the disease [4]. Therefore, the 
discovery of molecules which target the TNBC is 
desired for its treatment.  
 
The commonly used chemotherapeutic agents 
for cancer treatment are antibiotics belonging to 
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the anthracycline, bleomycin, actinomycin, 
mitomycin and aureolic acid families [7]. Among 
these families, anthracyclines exhibit promising 
anti-tumor activities through the suppression of 
topoisomerase II [8,9]. Another important natural 
isolate wortmannin from the fungus Talaromyces 
wortmanni has been shown to act as inhibitor of 
signal transduction pathways targeting 3 kinase 
(PI3K) activity [10]. Targeting signal transduction 
cascades by involvement of bioactive 
compounds is believed to be a promising 
strategy for carcinoma therapy [11]. The present 
study was designed to investigate the effect of 
wortmannin on breast carcinoma inhibition, miR 






Cell lines and culture  
 
Human breast carcinoma cell lines, BT-20 and 
BT-474 were purchased from the Riken 
Bioresource Center (Tsukuba, Japan). The cells 
were cultured in cultured Dulbecco's modified 
Eagle's medium/F-12 (DMEM/F-12) (Wako) 
supplemented with 10 % fetal bovine serum 




Wortmannin was isolated from the fungus, 
Talaromyces wortmanni, using solvent extraction 
followed by column chromatography in 10 % 
methanol and chloroform. 
 
Xenograft model of tumorigenesis 
 
Athymic nu/nu 6-week-old female mice (Harlan 
Sprague-Dawley) were fed irradiated sterile food 
and water. The mice were acclimatized to the 
laboratory environment one week before the 
experiment was started. The animals were 
randomly assigned to 4 groups with 10 each, BT-
20 control, BT-20 treatment, BT-474 control and 
BT-474 treatment groups. The animals were 
injected with BT-20 or BT-474 cells (2.5 x 105) in 
the mammary fat pad under anesthesia. The 
animals in the treatment groups were given 
wortmannin (7 mg/kg) in DMSO daily 
intraperitoneally whereas the animals in control 
groups received equal volume of DMSO for 21 
days after the cancer attained palpable stage. 
During the treatment period volume of cancerous 
mass was calculated after every 2 days by 
measuring the tumor size with digital calipers. 
After the completion of the treatment, the animals 
were sacrificed to extract the tumors, uterus, 
liver, and lungs. The tissues were immediately 
fixed in formalin and stored under cold conditions 
using liquid nitrogen. The liquid nitrogen frozen 
samples were then used for other analyses.  
 
The animal experiments were performed 
according to the rules of the ethical committee of 
the Weifang People’s Hospital, No. 207 
Guangwen Street, Kuiwen District, Weifang, 
Shandong. All measures were taken to minimize 
suffering in the animal.  
 
Western blot analysis 
 
The cells after treatment with wortmannin were 
washed with phosphate-buffered saline (PBS) 
and lysed in lysis buffer containing aprotinin (10 
mg/mL), leupeptin (10 mg/mL) (ICN Biomedicals, 
Inc., Asse Relegem, Belgium) and 
phenylmethylsulfonyl fluoride (Sigma-Aldrich). 
The proteins were separated on SDS-PAGE, 
loaded on PVDF and treated with primary 
antibodies. After incubation the membrane was 
incubated with secondary antibodies conjugated 
to horseradish peroxidase. The blots were 
examined using enhanced chemiluminescence 




The cells, after treatment with wortmannin or 
normal saline for 24 h, were subjected to 2D 
electrophoresis. Protean IEF cell unit (BioRad, 
Hercules, CA, USA) was used for 1-D 
electrophoresis and the proteins were separated 
using Precast 11 cm IPG strips. BioRad Criterion 
electrophoresis cell system was employed for 2-
D electrophoresis and Gel Doc XR image system 
(BioRad) was used for analysis of stained gels. 
The scanned gels were analyzed with PDQuest 




All the experiments were performed in triplicate. 
Student t-test or analysis of variance (ANOVA) 
was used for statistical analysis. Differences 





Inhibition of breast carcinoma growth  
 
The animals in both treatment and control groups 
were administered carcinoma cells, BT-20 or BT-
474 along with reduced growth factor matrigel 
(Fig 1A,B). When the tumor attained palpable 
stage, animals in the treatment group were given 
wortmannin (7 mg/kg/day) and those of control 
group received an equal volume of normal saline. 
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It was observed that the volume of tumor in 
treatment group was markedly small compared 
to control group. The tumor volume in the 
treatment and control groups were 42.72 ± 9.45 
and 79.43 ± 17.11 mm3, respectively after the 
completion of the treatment period. 
 
Effect of wortmannin on the miRnome 
 
The BT-20 cells on exposure to wortmannin for 
24 h showed prominent changes in the 
expression of miRNA whereas no such changes 
were observed in untreated control cells. 
Wortmannin treatment significantly enhanced the 
expression of some of the miRs including miR 
19a/b, 22, 29b/c, 181c/d, 195 and 663 (Figure 
2A). In addition wortmannin treatment inhibited 
the expression of some of the miRs including, 





Figure 1: Suppression of tumor growth by wortmannin in breast carcinoma. The mice were administered (A) BT-







  Figure 2: Effect of wortmanninon microRNA expression in BT-20 cells after 24 h 
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Wortmannin changes the proteome of BT-20 
breast carcinoma cells 
 
Exposure of BT-20 cells to wortmannin for 24 h 
induced changes in the expression of proteomes. 
The results from Western blot analysis showed 
increase in the expression of NME1 (NM23 H1) 
by wortmannin treatment (Figure 3). The 
expression of vimentin was significantly 










In cancerous tissues miR expression shows 
changes which are known to be associated with 
increase in tumor growth, resistance to drugs 
and spread of cancer cells [16-18]. The results 
obtained in the present study showed that 
wortmannin induces expression of miRs and thus 
acts as suppresser of tumor growth. It has been 
reported that miRs exhibits anti-carcinoma effect 
on tumor growth by interfering with the 
expression of Jun B and Jun D [19]. miR 19 
suppresses the expression of tissue factor which 
is involved in the progress of tumors [20]. The 
results from the present study revealed increase 
in the expression of tumor suppressor genes on 
exposure to wortmannin. Studies have 
demonstrated that miR 193a 5p genes play an 
important role in the progression of tumor growth 
[21]. In the present study it was observed that the 
expression of the genes was inhibited by 
exposure to wortmannin. 
 
It is reported that miR 21 gene is responsible for 
inducing resistance to drugs resulting in poor 
tumor prognosis rate [22,23]. Wortmannin 
induced inhibition of these genes and thus 
prevented the development of resistance to 
drugs. A surface marker found during change of 
epithelial cells to mesenchymal cells is over-
expressed in breast cancer cells [15]. The 
expression of vimentin is significantly enhanced 
following treatment with wortmannin. Therefore, 
wortmannin suppresses the growth of tumors in 




Wortmannin inhibits the growth of breast 
carcinoma cells via change in expression of miR. 
Thus, wortmannin can be used for the treatment 
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